What Is AOD-9604? Research Evidence & Profile

What Is AOD-9604?

AOD-9604 is a modified peptide analogue identified in the literature as Tyr-hGH(177–191), rather than the unmodified hGH fragment. This page identifies the material as Human Growth Hormone Fragment 176-191 (AOD-9604), with amino acid count 16; synonyms hGH fragment 176-191 analogue. The AOD-9604 identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

0ClinicalTrials.gov query records

4PubMed query records

4Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for AOD-9604 is organized around peptide-fragment comparison, modified peptide characterization, receptor-pathway research, and analytical peptide profiling. For AOD-9604, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
No exact-match registry records were returned by the displayed query at the retrieval time.

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature4 important records shown

Selected Literature

Selected PubMed record

Hyperglycemic action of synthetic C-terminal fragments of human growth hormone.

The American journal of physiology · 1978 May

PMID 645904

Selected PubMed record

Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.

Drug design, development and therapy · 2022

PMID 35783198

Selected PubMed record

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

Frontiers in endocrinology · 2026

PMID 42395176

Selected PubMed record

The mechanism of the hyperglycaemic action of synthetic peptides related to the C-terminal sequence of human growth hormone.

Biochimica et biophysica acta · 1982 Jun 16

PMID 6810951

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: Human Growth Hormone Fragment 176-191 (AOD-9604)
Available Specifications: 2mg, 5mg, 10mg
Pack Format: 10 Vials
CAS Number: 221231-10-3
Molecular Formula: C78H123N23O23S2
Molecular Weight: 1815.08 g/mol
Amino Acid Count: 16
Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (disulfide Cys7-Cys15)
Synonyms: hGH fragment 176-191 analogue
Physical Form: Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 71300630 · Product form must still be matched to the catalogue and batch record.

Research Tools for AOD-9604

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

AOD-9604 Research Summary

Identity

Human Growth Hormone Fragment 176-191 (AOD-9604); specifications: 2mg, 5mg, 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

Evidence

0 registry records and 4 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

AOD-9604 is represented here by the catalogue identity Human Growth Hormone Fragment 176-191 (AOD-9604). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 2mg, 5mg, 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for AOD-9604 is organized around peptide-fragment comparison, modified peptide characterization, receptor-pathway research, and analytical peptide profiling. For AOD-9604, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 0 ClinicalTrials.gov records and 4 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

AOD-9604 FAQ

What is AOD-9604?

What research records are indexed for AOD-9604?

The synchronized query returned 0 ClinicalTrials.gov records and 4 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is AOD-9604 FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.